Enaltec has successfully received 4 ANDA (Abbreviated New Drug Application) approvals from USFDA which are commercialised in US market. We are also expecting 1 more ANDA approvals by end of June 2022. These products are available for out-licensing in non-US markets and tailor fit dossiers can be provided for respective markets.